Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024:185:67-78.
doi: 10.1016/bs.mcb.2024.02.005. Epub 2024 Mar 5.

Peritoneal carcinomatosis in mouse models

Affiliations

Peritoneal carcinomatosis in mouse models

Leire Arrizabalaga et al. Methods Cell Biol. 2024.

Abstract

Peritoneal carcinomatosis (PCa) represents a metastatic stage of a disease with unmet therapeutic options. Malignant cells from primary tumors (gastrointestinal or gynecologic malignancies) invade the peritoneal cavity and eventually seed onto peritoneal surfaces, with the omentum being the most common nest area. With a median survival of less than 6 months, PCa has a dismal prognosis that can be improved with treatments only available to a select few individuals with low tumor burden. Thus, the discovery of novel and effective therapies for this disease depends on reliable animal models. Here, we describe a method to generate syngeneic PCa mouse models based on intraperitoneal (i.p.) administration of tumor cells. This model allows to follow-up cancer progression in PCa models from ovarian and colorectal origins monitoring mice bodyweight changes, ascites development and overall survival. Moreover, luciferase-expressing tumor cells can also be used to assess tumor growth after i.p. injection through in vivo bioluminescence quantification. The establishment of reliable, easy-to-monitor and reproducible intraperitoneal syngeneic tumors models, as described here, is the first step to develop cutting-edge therapies against PCa.

Keywords: Animal models; Ascites; Omentum; Peritoneal carcinomatosis; Tumor models.

PubMed Disclaimer

Conflict of interest statement

Disclosures This study was supported by Instituto de Salud Carlos III (PI19/01128, and PI20/00002) co-financed by Fondos Feder and Gobierno de Navarra Proyecto ARNMUNE Ref: 0011-1411-2023. P.B. receives a 2022 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation). F.A. receives a Miguel Servet I (CP19/00114) contract from ISCIII (Instituto de Salud Carlos III) co-financed by FSE (Fondo Social Europeo). A.B. is the recipient of PFIS fellowship from ISCIII (FI20/00058), and L.A. receives a FPU grant (FPU21/00042) from Spanish Ministry of Education and Professional training.

LinkOut - more resources